APO Research
Talk to an analyst

APO RESEARCH · REPORT

DNA Gyrase Subunit B (EC 5.99.1.3)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Outlook and Growth Opportunities 2026

19 December 2025198 pages

Choose your research edition.

Industry ResearchDNA Gyrase Subunit B (EC 5.99.1.3) Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal DNA Gyrase Subunit B (EC 5.99.1.3) Industry Growth and Trends Forecast to 203264 pages · $3,450 USDMarket StructureGlobal DNA Gyrase Subunit B (EC 5.99.1.3) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032178 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal DNA Gyrase Subunit B (EC 5.99.1.3) Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal DNA Gyrase Subunit B (EC 5.99.1.3) Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global DNA Gyrase Subunit B (EC 5.99.1.3) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for DNA Gyrase Subunit B (EC 5.99.1.3) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for DNA Gyrase Subunit B (EC 5.99.1.3) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for DNA Gyrase Subunit B (EC 5.99.1.3) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the DNA Gyrase Subunit B (EC 5.99.1.3) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the DNA Gyrase Subunit B (EC 5.99.1.3) market include Merck & Co., Inc., AstraZeneca Plc, Daiichi Sankyo Company Ltd and Abgentis Limited, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global DNA Gyrase Subunit B (EC 5.99.1.3) market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of DNA Gyrase Subunit B (EC 5.99.1.3) and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents DNA Gyrase Subunit B (EC 5.99.1.3) revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global DNA Gyrase Subunit B (EC 5.99.1.3) market.

DNA Gyrase Subunit B (EC 5.99.1.3) Segment by Company

Merck & Co., Inc.

AstraZeneca Plc

Daiichi Sankyo Company Ltd

Abgentis Limited

DNA Gyrase Subunit B (EC 5.99.1.3) Segment by Type

VXC-100

VT-12008911

GYR-12

DS-2969

Others

DNA Gyrase Subunit B (EC 5.99.1.3) Segment by Application

Bacterial Infections

Clostridium Diffclie Infections

Klebsiella Pneumoniae Infections

Others

DNA Gyrase Subunit B (EC 5.99.1.3) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global DNA Gyrase Subunit B (EC 5.99.1.3) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the DNA Gyrase Subunit B (EC 5.99.1.3) key companies, revenue, market share, and recent developments.

3. To split the DNA Gyrase Subunit B (EC 5.99.1.3) breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions DNA Gyrase Subunit B (EC 5.99.1.3) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify DNA Gyrase Subunit B (EC 5.99.1.3) significant trends, drivers, influence factors in global and regions.

6. To analyze DNA Gyrase Subunit B (EC 5.99.1.3) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DNA Gyrase Subunit B (EC 5.99.1.3) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of DNA Gyrase Subunit B (EC 5.99.1.3) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DNA Gyrase Subunit B (EC 5.99.1.3).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global DNA Gyrase Subunit B (EC 5.99.1.3) industry.

Chapter 3: Detailed analysis of DNA Gyrase Subunit B (EC 5.99.1.3) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of DNA Gyrase Subunit B (EC 5.99.1.3) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of DNA Gyrase Subunit B (EC 5.99.1.3) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. DNA Gyrase Subunit B (EC 5.99.1.3) Industry Trends Table 2. DNA Gyrase Subunit B (EC 5.99.1.3) Industry Drivers Table 3. DNA Gyrase Subunit B (EC 5.99.1.3) Industry Opportunities and Challenges Table 4. DNA Gyrase Subunit B (EC 5.99.1.3) Industry Restraints Table 5. Global DNA Gyrase Subunit B (EC 5.99.1.3) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global DNA Gyrase Subunit B (EC 5.99.1.3) Revenue Share by Company (2021-2026) Table 7. Global DNA Gyrase Subunit B (EC 5.99.1.3) Company Ranking, (2024-2026) & (US$ Million) Table 8. Global DNA Gyrase Subunit B (EC 5.99.1.3) Key Company Manufacturing Base & Headquarters Table 9. Global DNA Gyrase Subunit B (EC 5.99.1.3) Company, Product Type & Application Table 10. Global DNA Gyrase Subunit B (EC 5.99.1.3) Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global DNA Gyrase Subunit B (EC 5.99.1.3) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of VXC-100 Table 15. Significant Companies of VT-12008911 Table 16. Significant Companies of GYR-12 Table 17. Significant Companies of DS-2969 Table 18. Significant Companies of Others Table 19. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type (2021-2026) Table 23. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Bacterial Infections Table 25. Significant Companies of Clostridium Diffclie Infections Table 26. Significant Companies of Klebsiella Pneumoniae Infections Table 27. Significant Companies of Others Table 28. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application (2021-2026) Table 32. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application (2027-2032) Table 33. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Region (2021-2026) Table 36. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Region (2027-2032) Table 38. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Market Share by Country (2021-2026) Table 41. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Market Share by Country (2027-2032) Table 43. Merck & Co., Inc. Company Information Table 44. Merck & Co., Inc. Business Overview Table 45. Merck & Co., Inc. DNA Gyrase Subunit B (EC 5.99.1.3) Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Merck & Co., Inc. DNA Gyrase Subunit B (EC 5.99.1.3) Product Portfolio Table 47. Merck & Co., Inc. Recent Development Table 48. AstraZeneca Plc Company Information Table 49. AstraZeneca Plc Business Overview Table 50. AstraZeneca Plc DNA Gyrase Subunit B (EC 5.99.1.3) Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. AstraZeneca Plc DNA Gyrase Subunit B (EC 5.99.1.3) Product Portfolio Table 52. AstraZeneca Plc Recent Development Table 53. Daiichi Sankyo Company Ltd Company Information Table 54. Daiichi Sankyo Company Ltd Business Overview Table 55. Daiichi Sankyo Company Ltd DNA Gyrase Subunit B (EC 5.99.1.3) Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Daiichi Sankyo Company Ltd DNA Gyrase Subunit B (EC 5.99.1.3) Product Portfolio Table 57. Daiichi Sankyo Company Ltd Recent Development Table 58. Abgentis Limited Company Information Table 59. Abgentis Limited Business Overview Table 60. Abgentis Limited DNA Gyrase Subunit B (EC 5.99.1.3) Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Abgentis Limited DNA Gyrase Subunit B (EC 5.99.1.3) Product Portfolio Table 62. Abgentis Limited Recent Development Table 63. Research Programs/Design for This Report Table 64. Authors List of This Report Table 65. Secondary Sources Table 66. Primary Sources List of Figures Figure 1. DNA Gyrase Subunit B (EC 5.99.1.3) Product Image Figure 2. Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Size (2021-2032) & (US$ Million) Figure 4. Global DNA Gyrase Subunit B (EC 5.99.1.3) Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. VXC-100 Image Figure 8. VT-12008911 Image Figure 9. GYR-12 Image Figure 10. DS-2969 Image Figure 11. Others Image Figure 12. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type (2021-2032) Figure 15. Bacterial Infections Image Figure 16. Clostridium Diffclie Infections Image Figure 17. Klebsiella Pneumoniae Infections Image Figure 18. Others Image Figure 19. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application (2021-2032) Figure 22. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value (2021-2032) & (US$ Million) Figure 25. North America DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value (2021-2032) & (US$ Million) Figure 27. Europe DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value (2021-2032) & (US$ Million) Figure 31. South America DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • VXC-100
  • VT-12008911
  • GYR-12
  • DS-2969
  • Others
Applications
  • Bacterial Infections
  • Clostridium Diffclie Infections
  • Klebsiella Pneumoniae Infections
  • Others
Companies covered
  • Merck & Co., Inc.
  • AstraZeneca Plc
  • Daiichi Sankyo Company Ltd
  • Abgentis Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 DNA Gyrase Subunit B (EC 5.99.1.3) Market Dynamics
  1. 2.1 DNA Gyrase Subunit B (EC 5.99.1.3) Industry Trends
  2. 2.2 DNA Gyrase Subunit B (EC 5.99.1.3) Industry Drivers
  3. 2.3 DNA Gyrase Subunit B (EC 5.99.1.3) Industry Opportunities and Challenges
  4. 2.4 DNA Gyrase Subunit B (EC 5.99.1.3) Industry Restraints
3 DNA Gyrase Subunit B (EC 5.99.1.3) Market by Company
  1. 3.1 Global DNA Gyrase Subunit B (EC 5.99.1.3) Company Revenue Ranking in 2025
  2. 3.2 Global DNA Gyrase Subunit B (EC 5.99.1.3) Revenue by Company (2021-2026)
  3. 3.3 Global DNA Gyrase Subunit B (EC 5.99.1.3) Company Ranking (2024-2026)
  4. 3.4 Global DNA Gyrase Subunit B (EC 5.99.1.3) Company Manufacturing Base and Headquarters
  5. 3.5 Global DNA Gyrase Subunit B (EC 5.99.1.3) Company Product Type and Application
  6. 3.6 Global DNA Gyrase Subunit B (EC 5.99.1.3) Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 DNA Gyrase Subunit B (EC 5.99.1.3) Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 DNA Gyrase Subunit B (EC 5.99.1.3) Market by Type
  1. 4.1 DNA Gyrase Subunit B (EC 5.99.1.3) Type Introduction
  2. 4.1.1 VXC-100
  3. 4.1.2 VT-12008911
  4. 4.1.3 GYR-12
  5. 4.1.4 DS-2969
  6. 4.1.5 Others
  7. 4.2 Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Type
  8. 4.2.1 Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Type (2021-2032)
  10. 4.2.3 Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type (2021-2032)
5 DNA Gyrase Subunit B (EC 5.99.1.3) Market by Application
  1. 5.1 DNA Gyrase Subunit B (EC 5.99.1.3) Application Introduction
  2. 5.1.1 Bacterial Infections
  3. 5.1.2 Clostridium Diffclie Infections
  4. 5.1.3 Klebsiella Pneumoniae Infections
  5. 5.1.4 Others
  6. 5.2 Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Application
  7. 5.2.1 Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Application (2021-2032)
  9. 5.2.3 Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application (2021-2032)
6 DNA Gyrase Subunit B (EC 5.99.1.3) Regional Value Analysis
  1. 6.1 Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Region (2021-2032)
  3. 6.2.1 Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Region: 2021-2026
  4. 6.2.2 Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value (2021-2032)
  7. 6.3.2 North America DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value (2021-2032)
  10. 6.4.2 Europe DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value (2021-2032)
  16. 6.6.2 South America DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Country, 2025 VS 2032
7 DNA Gyrase Subunit B (EC 5.99.1.3) Country-level Value Analysis
  1. 7.1 Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Country (2021-2032)
  3. 7.2.1 Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Country (2021-2026)
  4. 7.2.2 Global DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt DNA Gyrase Subunit B (EC 5.99.1.3) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck & Co., Inc.
  2. 8.1.1 Merck & Co., Inc. Company Information
  3. 8.1.2 Merck & Co., Inc. Business Overview
  4. 8.1.3 Merck & Co., Inc. DNA Gyrase Subunit B (EC 5.99.1.3) Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck & Co., Inc. DNA Gyrase Subunit B (EC 5.99.1.3) Product Portfolio
  6. 8.1.5 Merck & Co., Inc. Recent Developments
  7. 8.2 AstraZeneca Plc
  8. 8.2.1 AstraZeneca Plc Company Information
  9. 8.2.2 AstraZeneca Plc Business Overview
  10. 8.2.3 AstraZeneca Plc DNA Gyrase Subunit B (EC 5.99.1.3) Revenue and Gross Margin (2021-2026)
  11. 8.2.4 AstraZeneca Plc DNA Gyrase Subunit B (EC 5.99.1.3) Product Portfolio
  12. 8.2.5 AstraZeneca Plc Recent Developments
  13. 8.3 Daiichi Sankyo Company Ltd
  14. 8.3.1 Daiichi Sankyo Company Ltd Company Information
  15. 8.3.2 Daiichi Sankyo Company Ltd Business Overview
  16. 8.3.3 Daiichi Sankyo Company Ltd DNA Gyrase Subunit B (EC 5.99.1.3) Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Daiichi Sankyo Company Ltd DNA Gyrase Subunit B (EC 5.99.1.3) Product Portfolio
  18. 8.3.5 Daiichi Sankyo Company Ltd Recent Developments
  19. 8.4 Abgentis Limited
  20. 8.4.1 Abgentis Limited Company Information
  21. 8.4.2 Abgentis Limited Business Overview
  22. 8.4.3 Abgentis Limited DNA Gyrase Subunit B (EC 5.99.1.3) Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Abgentis Limited DNA Gyrase Subunit B (EC 5.99.1.3) Product Portfolio
  24. 8.4.5 Abgentis Limited Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst